9px5 | pdb_00009px5
Crystal structure of Fab 7268 in complex with MBP-TREM2 Ig domain fusion
Structural highlights
DiseaseTREM2_HUMAN Progressive non-fluent aphasia;Amyotrophic lateral sclerosis;Nasu-Hakola disease;Semantic dementia;Behavioral variant of frontotemporal dementia. The disease is caused by mutations affecting the gene represented in this entry. FunctionMALE_ECOLI Involved in the high-affinity maltose membrane transport system MalEFGK. Initial receptor for the active transport of and chemotaxis toward maltooligosaccharides.TREM2_HUMAN May have a role in chronic inflammations and may stimulate production of constitutive rather than inflammatory chemokines and cytokines. Forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells.[1] Publication Abstract from PubMedTriggering Receptor Expressed on Myeloid cells 2 (TREM2) plays an important role in microglial function and has been genetically linked to Alzheimer's disease. Activation of TREM2 signaling may contribute to protection against neurotoxic effects of amyloid. Numerous TREM2 activating antibodies have been shown to modulate downstream microglial functions to different degrees, with mixed results in preclinical models and in the clinic. We sought to generate an effectorless agonistic antibody that acted solely through TREM2 engagement with sufficient potency to activate TREM2 in the brain. Our approach focused on building a multivalent biparatopic TREM2 antibody that could mimic the higher order clustering induced by native polyanionic ligands of TREM2. We describe our screening strategy and findings that led to the discovery of a potential therapeutic molecule composed of antibodies selected for optimal affinity, binding epitopes, and geometry. The most productive antibody pair was selected from a common light chain yeast-display library, which required multiple rounds of affinity maturation. Lead antibody candidates were converted into asymmetric tetravalent bispecifics via controlled Fab-arm exchange and subsequently screened in signaling assays. The most productive antibody pair was reengineered into a symmetric tetravalent format, increasing potency and simplifying development. This molecule exhibited higher efficacy and potency in signaling assays than other antibody formats tested and elicited TREM2-mediated chemokine responses in vivo. Our results demonstrate a biparatopic strategy for producing a high potency TREM2 agonistic antibody with low effector function that can modulate TREM2 signaling in vitro and brain pharmacodynamic responses in vivo. Building a potent TREM2 agonistic, biparatopic, common light chain antibody.,da Silva Almeida A, Geddie ML, Bhate A, Quan C, Arndt JW, Jiao Y, Santoro JC, Noiman L, Vijayakumar R, Sanchez-Salazar J, Datta A, Antognetti G, Hartana CA, Wang XF, Smith BA, Bartlett D, Duncan D, Liu CC, Otero Gutierrez K, Cameron TO, Koirala S, Cooke HA MAbs. 2025 Dec;17(1):2546554. doi: 10.1080/19420862.2025.2546554. Epub 2025 Aug , 13. PMID:40803893[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||||
